Table 1.
Immunotherapy using inactivated tumor cells and a gene modified tumor vaccine (GMTV).
| Authors | Vaccine | Adjuvant | Patients | Duration of PFS/RFS | Results |
|---|---|---|---|---|---|
| Galligioni | Auto irrad tumor | BCG | 120 | 13 mo | 5-year DFS 63% |
| (control 72%) P = .21 | |||||
| Schwaab | Auto irrad tumor | BCG, IFN-α, IFN-γ | 14 | — | 3 MR, 5 SD, l PD |
| Dillman | Auto irrad tumor | BCG, IFN-α, IFN-β | 25 | 2.4 mo | median survival 33.4 mo, |
| GM-CSF, Cy | 5-year survival 43% | ||||
| Jocham | Auto lysate | None | 379 | 47.8 mo | 5-year PFS 77.4% |
| (control 67.8%) P = .02 | |||||
| Dudek | Auto LMI | None, Cy, Cy+IL-2 | 31 | 2.8 mo | None: 5 SD, Cy: 4 SD, |
| Cy+ IL-2: 1PR 3 SD | |||||
| May | Auto lysate | None | 495 | — | 5 year,10 year OS: 80.6, 68.9% |
| (control 79.2, 62.1%) P = .066 | |||||
| Simons | Auto irrad tumor | None | 16 | — | 1 PR |
| + GM-CSF | |||||
| Wittig | Auto irrad tumor | Oligonucleotides | 10 | — | 1 CR, 1 PR, 1 MR, 2 SD, 5 PD |
| + GM-CSF, IL-7 | |||||
| Antonia | Auto irrad tumor | IL-2 | 15 | — | 2 PR, 2 SD |
| + B7.1 gene | |||||
| Tani | Auto irrad tumor | None | 6 | — | 1 SD, l MR |
| + GM-CSF | |||||
| Pizza | Auto irrad tumor | None | 30 | 170.5 dy | 1 CR, 4 PR, 9 SD |
| + IL-2 | |||||
| Moiseyenko | Auto irrad tumor | None | 3 mo | 1 SD, l MR | |
| + tag7/PGPR-S gene | 4 | ||||
| Fishman | Auto irrad tumor | IL-2 | 39 | — | 1 CR, 2 PR, 24 SD |
| + B7.1 gene | |||||
| Buchner | Auto irrad tumor | None | 12 | 5.3 mo | PFS 5.3 mo, OS 15.6 mo |
| + B7.1, IL-2 gene |
LMI: large multivalent immunogen, Cy: cyclophosphamide, DFS: disease-free survival, Os: overall survival, PR: partial response, MR: mixed response, SD: stable disease, PD: progressive disease, PFS: progression-free survival, RFS: recurrence-free survival.